One of the few pharmaceutical groups in the world to master various advanced Bioproduction techniques, the LFB group is an expert in plasma-derived medicinal products, ranking 6th player worldwide and 1st in France in this field.
The group also masters the development and manufacture of active monoclonal antibodies, and develops a line of recombinant proteins using a disruptive technology, rPRO™.

Since 1994, the LFB group has developed, manufactured and marketed cutting-edge biopharmaceuticals to treat serious, often rare diseases, in the areas of Immunology, Hemostasis, Perinatal and Intensive Care. LFB’s medicinal products are under hospital prescription and allow healthcare professionals to hundreds of thousands of patients every year, in France and in more than 40 countries in the world.